Plunkett Research Online: Intercept Pharmaceuticals Inc

INTERCEPT PHARMACEUTICALS INC (ICPT:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva for the treatment of primary biliary cirrhosis in 2016 and is .....



Intercept Pharmaceuticals Inc
Ticker: ICPT
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 646 747-1000
Fax: 1 646 747-1001
Address: 450 West 15th Street
Suite 505
New York, NY 10011 United States

Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
ContactsDescription
Mark PruzanskiCEO/Co-Founder/Director/President
Sandip KapadiaCFO/Chief Accounting Officer/Treasurer
See More
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva for the treatment of primary biliary cirrhosis in 2016 and is .....See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201620152014201320122011
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: